Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edi Brogi

Showing results (211-220 of 214) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 214 results.
Cancer Research|August 6, 2024
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating MechanismsFresia Pareja, Higinio Dopeso, Yi Kan Wang, et al.
Cancer Cell|September 12, 2018
The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersPedram Razavi, Matthew T Chang, Guotai Xu, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Pageof 22

Showing results (211-220 of 214) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 214 results.
Cancer Research|August 6, 2024
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating MechanismsFresia Pareja, Higinio Dopeso, Yi Kan Wang, et al.
Cancer Cell|September 12, 2018
The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersPedram Razavi, Matthew T Chang, Guotai Xu, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Pageof 22